Loading clinical trials...
Loading clinical trials...
An Observer-blind Study to Rank Different Formulations of GSK Biologicals' Investigational RSV Vaccine (GSK3003891A) Administered to Healthy Women
Conditions
Interventions
RSV Vaccine (GSK3003891A) formulation 1
RSV Vaccine (GSK3003891A) formulation 2
+2 more
Locations
8
Belgium
GSK Investigational Site
Ghent, Belgium
GSK Investigational Site
Tallinn, Estonia
GSK Investigational Site
Tartu, Estonia
GSK Investigational Site
Clermont-Ferrand, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Würzburg, Bavaria, Germany
Start Date
November 10, 2016
Primary Completion Date
August 30, 2017
Completion Date
February 5, 2018
Last Updated
July 2, 2019
NCT07220109
NCT07092865
NCT07239583
NCT06534892
NCT04919109
NCT07235397
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions